April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Diabetes Increases 12-Lipoxygenase Expression in Human and Mouse Retinas
Author Affiliations & Notes
  • M. A. Al-Shabrawey, II
    Oral Biology/Sch of Dentistry,
    Ophthalmology,
    Medical College of Georgia, Augusta, Georgia
  • R. Mussell
    Oral Biology/Sch of Dentistry,
    Medical College of Georgia, Augusta, Georgia
  • G. I. Liou
    Ophthalmology,
    Medical College of Georgia, Augusta, Georgia
  • S. K. Akeel
    Oral Biology/Sch of Dentistry,
    Medical College of Georgia, Augusta, Georgia
  • A. M. Tawfik
    Oral Biology/Sch of Dentistry,
    Medical College of Georgia, Augusta, Georgia
  • Footnotes
    Commercial Relationships  M.A. Al-Shabrawey, II, None; R. Mussell, None; G.I. Liou, None; S.K. Akeel, None; A.M. Tawfik, None.
  • Footnotes
    Support  American Heart Association and PSRP from MCG
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5370. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. A. Al-Shabrawey, II, R. Mussell, G. I. Liou, S. K. Akeel, A. M. Tawfik; Diabetes Increases 12-Lipoxygenase Expression in Human and Mouse Retinas. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5370.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Diabetic retinopathy is a vision threatening complication of diabetes associated with vascular damage and retinal cell apoptosis. 12- hydroxyeicosatetraenoic acid (12-HETE) is a biologically active metabolite of arachidonic acid produced by 12-lipoxygenase enzyme (12-LO). 12- HETE has been shown to induce leukocyte/endothelial interaction and neuronal cell death, both are major processes involved in the pathogenesis of diabetic retinopathy. However, the specific role of 12-HETE in diabetic retinopathy has not yet been elucidated. So, the goal of this study was to investigate the changes in the expression and activity of 12-LO in diabetic retina and correlating these changes with the vascular and neuronal cell injury associated with diabetic retinopathy.

Methods: : Expression of 12-LO and the inflammatory marker, intracellular adhesion molecule-1 (ICAM-1) was examined in retinas from human and streptozotocin-induced diabetic mice using Western blotting and immunofluroscence techniques. One group of diabetic mice was treated with 12-LO inhibitor baicalein (20mg/kg) for 12 weeks. Apoptotic cells in the retina were quantified using terminal dUTP nick-end labeling (TUNEL). We also tested the effect of baicalein on lipopolysacchardies (LPS)-induced ICAM-1 expression to evaluate the role of 12-LO in retinal inflammation.

Results: : Diabetes increased 12-LO expression in human and mouse retinas (2 and 1.5 fold respectively). This was associated with a marked increase in the level of ICAM-1 and number of apoptotic cells. Immunoflurosence showed that 12-LO expression was localized mainly in retinal vessels and related glial cells. Inhibition of 12-LO by baicalein treatment reduced the number of apoptotic cells and ICAM-1expression in diabetic and LPS injected mice.

Conclusions: : 12-LO plays a role in vascular and neuronal injury associated with diabetic retinopathy. Inhibition of 12-LO activity could be a new therapeutic strategy to treat diabetic retinopathy.

Keywords: diabetic retinopathy • eicosanoids • apoptosis/cell death 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×